GW Pharmaceuticals PLC Notice of Results (8904F)

TIDMGWP

RNS Number : 8904F

GW Pharmaceuticals PLC

02 August 2016

GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016

London, UK, 2 Aug 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 August, 2016 its third quarter financial results for the period ending 30 June, 2016. GW will also host a conference call the same day at 8:30 a.m. EDT (1:30 p.m. BST). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex(R) (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, LGS and Tuberous Sclerosis Complex. GW successfully commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc 
 Stephen Schultz, VP Investor Relations 
  (U.S.)                                   917 280 2424 / 401 500 6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway                 +44 20 3727 1000 
 FleishmanHillard (U.S. Media) 
 Paddi Hurley / Adam Silverstein           212 453 2382 / 917 697 9313 
 
 Peel Hunt LLP (UK NOMAD) 
 James Steel                               +44 20 7418 8900

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREFLFBQVFEBBX

(END) Dow Jones Newswires

August 02, 2016 07:00 ET (11:00 GMT)

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Nov 2024 to Dec 2024